# Translating Patent Innovation into Clinical Practice: Two Decades of Therapeutic Advancements in Dysbiosis Management

## TL;DR

This study tracks global innovation in managing dysbiosis through patents, showing a surge in bacterial-based therapies and diagnostics since 2014.

## Contribution

The novel contribution is a comprehensive analysis of two decades of dysbiosis-related patents, identifying key innovation trends and clusters.

## Key findings

- Patent filings for dysbiosis management grew exponentially, peaking at 1222 in 2022.
- Bacterial-based therapeutics dominated patent activity, comprising 44.8% of all patents analyzed.
- The United States led in patent publications, with 4361 documents from 2005 to 2024.

## Abstract

Dysbiosis, characterized by a microbial imbalance, particularly within the gut microbiota, has emerged as a significant health concern linked to various diseases. This study analyzed 8097 patent documents from The Lens database (2005–2024) to examine global innovation trends in dysbiosis management. The patent filings showed exponential growth, peaking at 1222 documents in 2022, with the United States leading in publications (4361 documents). The analysis revealed three primary innovation clusters: bacterial-based therapeutics (44.8% of patents), specific therapeutic applications (27.6%), and diagnostic methods (15.9%). The disease associations predominantly included inflammatory conditions, infections, and cancer. The patent classifications highlighted a significant focus on probiotic development and microbiota modulation. The surge in patent activity since 2014 correlates with advances in DNA sequencing technology and the growing recognition of dysbiosis’s role in human health. This analysis provides valuable insights into the evolving landscape of microbiome therapeutics and future directions for dysbiosis management.